Prestige Consumer Healthcare (NYSE:PBH) Upgraded at StockNews.com

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a buy rating in a research note released on Friday.

A number of other equities analysts have also commented on the stock. DA Davidson restated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a report on Monday, December 9th. Finally, Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $85.25.

Prestige Consumer Healthcare Price Performance

NYSE PBH opened at $76.79 on Friday. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The company has a market cap of $3.79 billion, a PE ratio of 18.68, a price-to-earnings-growth ratio of 2.17 and a beta of 0.51. Prestige Consumer Healthcare has a 52 week low of $60.00 and a 52 week high of $86.36. The firm’s 50-day simple moving average is $80.08 and its two-hundred day simple moving average is $74.93.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. During the same period in the prior year, the company posted $1.07 EPS. Prestige Consumer Healthcare’s revenue was down .9% compared to the same quarter last year. Research analysts predict that Prestige Consumer Healthcare will post 4.46 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider William P’pool sold 8,987 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the completion of the transaction, the insider now directly owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock valued at $3,187,300 over the last three months. Insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its holdings in shares of Prestige Consumer Healthcare by 19.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock valued at $113,570,000 after buying an additional 255,045 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Prestige Consumer Healthcare by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock worth $95,678,000 after buying an additional 50,961 shares during the last quarter. Congress Asset Management Co. grew its stake in shares of Prestige Consumer Healthcare by 7.8% in the 3rd quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock worth $62,375,000 after buying an additional 62,411 shares during the last quarter. Boston Trust Walden Corp increased its position in Prestige Consumer Healthcare by 43.5% during the 4th quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock valued at $64,942,000 after buying an additional 252,089 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Prestige Consumer Healthcare by 0.8% in the second quarter. The Manufacturers Life Insurance Company now owns 543,401 shares of the company’s stock worth $37,413,000 after acquiring an additional 4,305 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.